Premium
Surrogate endpoints in randomized cardiovascular clinical trials
Author(s) -
Domanski Michael,
Pocock Stuart,
Bernaud Corine,
Borer Jeffrey,
Geller Nancy,
Revkin James,
Zannad Faiez
Publication year - 2011
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.2010.00865.x
Subject(s) - surrogate endpoint , clinical endpoint , endpoint determination , medicine , clinical trial , randomized controlled trial , intensive care medicine
Surrogate endpoints predict the occurrence and timing of a clinical endpoint of interest (CEI). Substitution of a surrogate endpoint for a CEI can dramatically reduce the time and cost necessary to complete a Phase III clinical trial. However, assurance that use of a surrogate endpoint will result in a correct conclusion regarding treatment effect on a CEI requires prior rigorous validation of the surrogate. Surrogate endpoints can also be of substantial use in Phase I and II studies to assess whether the intended therapeutic pathway is operative, thus providing assurance regarding the reasonableness of proceeding to a Phase III trial. This paper discusses the uses and validation of surrogate endpoints.